ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Erectile Dysfunction Treatment Using Focused Linear Shockwaves
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 165970" data-attributes="member: 13851"><p><strong>Erectile Dysfunction Treatment Using Focused Linear Low-Intensity Extracorporeal Shockwaves: Single-Blind, Sham-Controlled, Randomized Clinical Trial </strong></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Abstract </span></strong></p><p></p><p><strong>Introduction:</strong> Low-intensity extracorporeal shock wave therapy (Li-ESWT) is a new treatment modality for erectile dysfunction (ED). Our aim was to evaluate the treatment outcome of Li-ESWT for ED in single-blind, placebo controlled, randomized clinical trial.</p><p></p><p><strong>Methods:</strong> Sixty patients were randomized into 2 age-matched groups: Group A – treatment and Group B – placebo. Treatment consisted of 4 sessions on the PiezoWave2 unit (R. Wolf and ELvation Medical). Effectiveness was assessed according to the International Index of Erectile Function 5 (IIEF-5), Erectile Hardness Score (EHS), questions 2 and 3 of the Sexual Encounter Profile (SEP 2, SEP 3), and Global Assessment Question (GAQ) scores at baseline and 4 and 12 weeks after treatment. We evaluated patient’s and partner’s subjective satisfaction.</p><p></p><p><strong>Results:</strong> A statistically significant difference between the groups was found at 4 and 12 weeks after treatment with regard to the quality of erection as measured by the IIEF-5 (p = 0.049 and p < 0.001, respectively), the EHS after week 12 (p < 0.001), an increase in the EHS after 4 and 12 weeks (p = 0.030 and p < 0.001, respectively), after 12 weeks in GAQ (p < 0.001), SEP 2 (p = 0.05), SEP 3 (p < 0.001), and patient’s satisfaction (p < 0.001) and partner’s satisfaction (p < 0.001).</p><p></p><p><strong>Conclusions:<span style="color: rgb(184, 49, 47)"> The randomized single-blind study confirms that Li-ESWT significantly improves erectile function. </span></strong></p><p></p><p><strong><span style="color: rgb(44, 130, 201)">Li-ESWT is a potential restorative therapy for post-RP ED; however, additional preclinical and clinical studies are required before its widespread use [32].</span></strong></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>Current nonsurgical treatment options of ED, including PDE5i, provide temporary relief but have failed to provide a permanent improvement of the condition.</strong></span> <span style="color: rgb(44, 130, 201)"><strong>The use of Li-ESWT has previously been described in other disease contexts, such as ischemic heart disease, bone fractures, and burns, in which it improves neoangiogenesis; similar principles seem to apply in the erectile tissue. The major potential advantage of the treatment, therefore, is the possibility to restore natural EF. Li-ESWT has also been suggested to improve the effect of PDE5i in non-responders, reducing the need for more invasive treatment.</strong></span> <span style="color: rgb(184, 49, 47)"><strong>The search for the clinical value of Li-ESWT for ED represents a dynamic and continuing field of enquiry [34]. </strong></span></p><p></p><p><span style="color: rgb(44, 130, 201)"><strong>Therapeutic potential of Li-ESWT is in sexual medicine other than ED. In Peyronie’s disease, Li-ESWT has been shown to decrease pain but not clinically relevant benefits regarding plaque size or penile curvature have been shown in randomized clinical trials.</strong></span> <span style="color: rgb(44, 130, 201)"><strong>The application of Li-ESWT to the tissue after stem cell transplantation may increase the erectile response following cavernous nerve injury due to diabetic damage. Li-ESWT has shown promise in pelvic pain. </strong></span><span style="color: rgb(184, 49, 47)"><strong>Other studies are needed, before considering this new treatment as the new standard for the treatment of ED [35]. </strong></span></p><p></p><p><strong>Limitations </strong></p><p></p><p><span style="color: rgb(26, 188, 156)"><strong>The limitations of the study are the relatively small number of patients, short follow-up period and only single-blind study.</strong></span></p></blockquote><p></p>
[QUOTE="madman, post: 165970, member: 13851"] [B]Erectile Dysfunction Treatment Using Focused Linear Low-Intensity Extracorporeal Shockwaves: Single-Blind, Sham-Controlled, Randomized Clinical Trial [/B] [B][COLOR=rgb(184, 49, 47)]Abstract [/COLOR][/B] [B]Introduction:[/B] Low-intensity extracorporeal shock wave therapy (Li-ESWT) is a new treatment modality for erectile dysfunction (ED). Our aim was to evaluate the treatment outcome of Li-ESWT for ED in single-blind, placebo controlled, randomized clinical trial. [B]Methods:[/B] Sixty patients were randomized into 2 age-matched groups: Group A – treatment and Group B – placebo. Treatment consisted of 4 sessions on the PiezoWave2 unit (R. Wolf and ELvation Medical). Effectiveness was assessed according to the International Index of Erectile Function 5 (IIEF-5), Erectile Hardness Score (EHS), questions 2 and 3 of the Sexual Encounter Profile (SEP 2, SEP 3), and Global Assessment Question (GAQ) scores at baseline and 4 and 12 weeks after treatment. We evaluated patient’s and partner’s subjective satisfaction. [B]Results:[/B] A statistically significant difference between the groups was found at 4 and 12 weeks after treatment with regard to the quality of erection as measured by the IIEF-5 (p = 0.049 and p < 0.001, respectively), the EHS after week 12 (p < 0.001), an increase in the EHS after 4 and 12 weeks (p = 0.030 and p < 0.001, respectively), after 12 weeks in GAQ (p < 0.001), SEP 2 (p = 0.05), SEP 3 (p < 0.001), and patient’s satisfaction (p < 0.001) and partner’s satisfaction (p < 0.001). [B]Conclusions:[COLOR=rgb(184, 49, 47)] The randomized single-blind study confirms that Li-ESWT significantly improves erectile function. [/COLOR][/B] [B][COLOR=rgb(44, 130, 201)]Li-ESWT is a potential restorative therapy for post-RP ED; however, additional preclinical and clinical studies are required before its widespread use [32].[/COLOR][/B] [COLOR=rgb(184, 49, 47)][B]Current nonsurgical treatment options of ED, including PDE5i, provide temporary relief but have failed to provide a permanent improvement of the condition.[/B][/COLOR] [COLOR=rgb(44, 130, 201)][B]The use of Li-ESWT has previously been described in other disease contexts, such as ischemic heart disease, bone fractures, and burns, in which it improves neoangiogenesis; similar principles seem to apply in the erectile tissue. The major potential advantage of the treatment, therefore, is the possibility to restore natural EF. Li-ESWT has also been suggested to improve the effect of PDE5i in non-responders, reducing the need for more invasive treatment.[/B][/COLOR] [COLOR=rgb(184, 49, 47)][B]The search for the clinical value of Li-ESWT for ED represents a dynamic and continuing field of enquiry [34]. [/B][/COLOR] [COLOR=rgb(44, 130, 201)][B]Therapeutic potential of Li-ESWT is in sexual medicine other than ED. In Peyronie’s disease, Li-ESWT has been shown to decrease pain but not clinically relevant benefits regarding plaque size or penile curvature have been shown in randomized clinical trials.[/B][/COLOR] [COLOR=rgb(44, 130, 201)][B]The application of Li-ESWT to the tissue after stem cell transplantation may increase the erectile response following cavernous nerve injury due to diabetic damage. Li-ESWT has shown promise in pelvic pain. [/B][/COLOR][COLOR=rgb(184, 49, 47)][B]Other studies are needed, before considering this new treatment as the new standard for the treatment of ED [35]. [/B][/COLOR] [B]Limitations [/B] [COLOR=rgb(26, 188, 156)][B]The limitations of the study are the relatively small number of patients, short follow-up period and only single-blind study.[/B][/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
Erectile Dysfunction Treatment Using Focused Linear Shockwaves
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top